Results 211 to 220 of about 2,253,953 (246)
Some of the next articles are maybe not open access.
Pathological Features of Antibody-Mediated Rejection
Current Drug Target -Cardiovascular & Hematological Disorders, 2005Although cell-mediated rejection has remained the most common form of graft rejection after organ transplantation, antibody-mediated rejection has recently gained much significance in clinical transplantation. New evidence points to an antibody-mediated rejection contributing not only to hyperacute and acute but also to chronic allograft rejection.
Akira, Shimizu, Robert B, Colvin
openaire +2 more sources
Treatment of Acute Antibody-Mediated Rejection
2017Acute antibody-mediated rejection (AMR) remains an important challenge in the field of kidney transplantation despite the advances in immunosuppressive strategies, and has been recognized as an important cause of allograft dysfunction and graft loss.
COMAI, GIORGIA +9 more
openaire +2 more sources
Management of Antibody-Mediated Rejection in Transplantation
Surgical Clinics of North America, 2013Despite intensive traditional immunosuppressive therapy, rates of graft loss have approximated 15% to 20% at 1 year following antibody-mediated rejection (AMR) in solid organ transplant recipients. Therefore, the development of antihumoral therapies that provide prompt elimination of donor-specific anti-HLA antibodies and improve allograft survival is ...
Basma, Sadaka +2 more
openaire +2 more sources
New insights in antibody-mediated rejection
Current Opinion in Nephrology and Hypertension, 2014In the present review, we aim to describe the state of knowledge concerning antibody-mediated rejection (ABMR) spectrum and diagnosis criteria before analyzing the present and future promising leads regarding ABMR prognosis markers and treatment.Recent studies regarding complement-binding donor-specific antibodies and the molecular approach highlighted
Clément, Gosset +2 more
openaire +2 more sources
Proteasome inhibition for antibody-mediated rejection
Current Opinion in Organ Transplantation, 2009The purpose of this review is to describe the biochemistry and physiology of proteasome inhibition and to discuss recent studies with proteasome inhibitor therapy in organ transplantation.Traditional antihumoral therapies do not deplete plasma cells, the source of antibody production.
Jason J, Everly +3 more
openaire +2 more sources
Acute Rejection and Antibody-Mediated Rejection in Lung Transplantation
Clinics in Chest Medicine, 2017Despite advances in immunosuppression over the past 25 years, acute cellular rejection remains a common complication early after lung transplantation. Although acute cellular rejection has often not resulted in clinical signs or symptoms of allograft dysfunction, it has been widely recognized as a strong independent risk factor for the development of ...
openaire +2 more sources
Antibody-Mediated Rejection of the Liver Allograft: An Update and a Clinico-Pathological Perspective
Journal of Hepatology, 2021Brian T Lee, M Isabel Fiel
exaly
Subclinical Antibody-Mediated Rejection
Transplantation, 2017Manuel, Arias +8 more
openaire +2 more sources
Felzartamab in Antibody-Mediated Rejection
New England Journal of MedicineStanley C, Jordan, Sanjeev, Kumar
openaire +3 more sources